Tennessee | 001-15875 | 54-1684963 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
||
501 Fifth Street, | 37620 | |||
Bristol, Tennessee | (Zip Code) | |||
(Address of Principal Executive Offices) |
o | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
þ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events. | ||||||||
Item 9.01. Financial Statements and Exhibits. | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
EX-99.1: PRESS RELEASE |
Item 8.01. | Other Events. |
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits |
99.1 | King Pharmaceuticals, Inc. Press Release, dated September 11, 2008. |
KING PHARMACEUTICALS, INC. |
||||
By: | /s/ Joseph Squicciarino | |||
Joseph Squicciarino | ||||
Chief Financial Officer | ||||